R-enantiomer of lansoprazole — proton pump inhibitor with delayed dual-release formulation (peaks at 1–2h and 4–5h) that extends acid suppression vs once-released PPIs. Approved for GERD + erosive esophagitis. CYP2C19 substrate.
Half-Life & Elimination Curve (PO: 1.7h)
Plasma (PO)t½ Decay (1.7h)
0×t½0h100%(0.932 mg/L)
1×t½1.7h50%(0.466 mg/L)
2×t½3.4h25%(0.233 mg/L)
3×t½5.1h12.5%(0.116 mg/L)
4×t½6.8h6.3%(58.2 µg/L)
5×t½8.5h3.1%(29.1 µg/L)
Elimination t½1.7h (PO)
Rate Constant (ke)0.408 h⁻¹
Time to Peak (Tmax)60m
Est. Peak (Cmax)0.932 mg/L
Clearance (CL)12.2 L/h
97% Washout (5×t½)8.5h
Dosing Guidelines
Oral (PO): Typical 60 mg (Range: 30–60 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 70% · Volume of Distribution (Vd): 30 L · Absorption (ka): 2 h⁻¹ (t½ka ≈ 21m) [PMID 28138748]
Pathways It Modulates
Gastric acid secretion (inhibitor) — H+/K+-ATPase (R-enantiomer with dual-release coating)